Syndenham’s chorea in Senegalese children: A case series
Objective: To describe clinical profile and treatment outcome of Sydenham’s chorea (SC) in children attending a tertiary care hospital in Dakar, Senegal. Background: SC is…Efficacy and safety of tetrabenazine in hyperkinetic movements disorders- An observational study
Objective: To assess the efficacy and side-effects of TBZ in Huntington disease (HD), vascular chorea, tics, dystonia, oromandibular dyskinesia and other tardive syndromes (TS). Background:…Prospective evaluation of pallidal deep brain stimulation in Huntington’s disease
Objective: To prospectively evaluate the effect of bilateral pallidal deep brain stimulation (DBS) on motor symptoms, activities of daily living and quality of life in…Clinical course and treatment of 6 children with GNAO1 mutations causing a severe, life-threatening chorea
Objective: We describe the clinical course of 6 patients with de novo GNAO1 mutations with severe chorea, developmental delay and hypotonia, but the absence of…Functional motor outcomes after globus pallidus internus deep brain stimulation in Huntington´s disease – A case report
Objective: The aim of this study was to analyse the motor outcome before and after 6 month follow-up in a HD patient treated by GPi-DBS.…A randomized, double-blind, placebo-controlled trial of deutetrabenazine for the treatment of tardive dyskinesia (ARM-TD)
Objective: To determine the efficacy and safety of deutetrabenazine (DTB) as a treatment for tardive dyskinesia (TD). Background: There is no approved treatment for TD,…A pilot study of SD-809 (deutetrabenazine) in tics associated with Tourette syndrome
Objective: This study explored the safety, tolerability and preliminary efficacy of SD-809 (deutetrabenazine) in adolescents with moderate to severe tics associated with Tourette syndrome (TS).…A randomized double-blind placebo- and positive-controlled crossover study to evaluate the effects of single doses of SD-809 (deutetrabenazine) and tetrabenazine on the corrected QT interval
Objective: Evaluate the pharmacokinetics and pharmacodynamics (QTc) of SD-809 (deutetrabenazine) and tetrabenazine. Background: SD-809 is a VMAT-2 inhibitor in clinical development for treatment of hyperkinetic…Verbatim patient-reported outcomes and trails making test B (TMT-B) performance in the REACH2HD trial
Objective: Examine the relationship between Trails Making Test B (TMT-B) performance and bothersome cognitive complaints among Huntington Disease (HD) research participants in the REACH2HD randomized-controlled…Program evaluation empowerment of people with Huntington’s disease (HD) and their families: Using goal attainment scaling (GAS)
Objective: The purposes of this study was evaluated the feasibility of psychosocial rehabilitation program designed to promotes automomy in people with HD and to describe…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.